Engineering Innovation from Concept to Commercialization
Better technology begins with better platforms.
Med-Ally Medical™, a division of QuantumStim™, is an engineering and product development engine dedicated to advancing innovative therapeutic medical technologies. Through a Patent to Patient™ (P2P™) approach, Med-Ally Medical™ supports every stage of Class II & III medical device development thru commercialization
Engineering with Purpose.
Med-Ally Medical™ brings together engineering, product development, regulatory support, manufacturing and program acceleration by leveraging its clinically proven Neuromodulation platform technologies, VersaStim®. By integrating these capabilities, Med-Ally Medical™ maintains the highest standards of quality, compliance, and patient safety.
Quality & Certification
Operating under FDA 21 CFR Part 820 regulations and an ISO 13485:2016-certified quality management system to deliver safe, reliable, and effective medical devices.
Risk Management
Guided by ISO 14971, Med-Ally Medical™ integrates comprehensive risk management throughout development to help ensure every device is designed with patient safety at its core.
Design & Development
Driven by innovation, Med-Ally Medical™ designs and develops Active Implantable Medical Devices and their supporting components to meet the unique needs of every application.
Innovation in Action
Med-Ally Medical™ platform technologies supports development initiatives clinically driven by QuantumStim Inc. and Physician partners, demonstrating its application across next-generation medical technologies.
NeuroFuse® DRG ULE™ represents the application of Med-Ally Medical™ platform technology to targeted dorsal root ganglion (DRG) neuromodulation utilizing ULE™ (Ultra Low Energy™) technology. Developed by SynerFuse®, the NeuroFuse® System is advancing clinical development to provide precise, integrated neuromodulation solutions for chronic neuropathic pain.
OmniPNS ULE™ (Ultra Low Energy™) represents the application of Med-Ally Medical™ platform technology to next-generation External Pulse Generator (EPG) solutions for peripheral nerve stimulation. QuantumStim™ is currently pursuing FDA 510(k) clearance for OmniPNS ULE™.
LEADERSHIP
Justin Zenanko
Chief Executive Officer
Justin Zenanko is the Founder and Chief Executive Officer of SynerFuse® and provides strategic leadership for Med-Ally Medical™. He oversees the company's long-term vision, commercialization strategy, and platform development, helping advance innovative medical technologies from concept to market. As a co-inventor of the SynerFuse® technology platform, Justin brings extensive experience in entrepreneurship, corporate finance, and medical device innovation.
Raja Hitti
Chief Technology Officer
Founder
Raja Hitti is the Founder and Chief Technology Officer of Med-Ally Medical™. With more than 30 years of experience in medical device engineering, manufacturing, and product development, he leads the design and advancement of the Med-Ally Medical™ platform technologies. His expertise spans active implantable medical devices, precision manufacturing, quality systems, and commercialization, helping transform innovative concepts into scalable medical technologies.
Nameer Haider, MD
Chief Innovation Officer
Dr. Nameer Haider serves as Chief Innovation Officer, providing clinical leadership that helps guide the development of the Med-Ally Medical™ engineering and platform technologies. An internationally recognized interventional pain specialist with more than 20 years of experience, he works closely with engineering teams to ensure new technologies are designed with physicians and patients at the center of every innovation.
Partner With Med-Ally Medical™
Med-Ally Medical™ provides the expertise and infrastructure to accelerate innovation.
Contact us to:
Learn about our engineering platform
Explore manufacturing capabilities
Discuss product development opportunities
Connect with our engineering team